NEOPLASMS

This study offers ongoing treatment with alectinib or crizotinib to 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche study. The main goal is to track side effects and safety while patients continue therapy. Participants …

This study tests a special type of immune cell (engineered T-cells) designed to recognize and attack cancer cells in people with advanced solid tumors. About 103 participants with specific genetic markers (HLA-A2) and tumor proteins (NY-ESO-1) will receive these cells alone or wi…

This study tests a personalized cell therapy called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not been treated before. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goal …

This study tests whether adding the drug dostarlimab to standard chemotherapy helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants will receive either the drug combo or a placebo plus chemo. The goal is to see…

This study tests a treatment called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not responded to prior therapy. The treatment uses specially engineered immune cells to target and attack the cancer. The goal is to see if it can shri…

This study tests a new oral drug (GSK4524101) alone and with another drug (niraparib) in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination shrinks tumors. About 42 participants will tak…

This study is testing a new experimental drug called GSK6097608, given alone or with other cancer drugs, in people with advanced solid tumors that have spread or come back. The main goal is to check safety and find the right dose. About 107 adults will take part. This is an early…

This study tests a new drug called E7386 combined with other anticancer drugs for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The main goals are to find safe doses and see if the combination shrinks tumors. About 301 adults will take p…

This study tests if bevacizumab, a drug that blocks blood vessel growth, can help adults with recurrent respiratory papillomatosis (RRP) go longer between surgeries to remove wart-like growths in the airways. About 21 participants who need at least two surgeries per year will rec…

This study is testing a combination of four drugs (irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab) as a second treatment option for people with advanced colorectal cancer that has spread and has a specific BRAF gene mutation. The goal is to see if this mi…

This early-phase study tests a new experimental drug (GSK3745417) alone or combined with another drug (dostarlimab) in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. …

This study offers extended access to the drug momelotinib for people with myelofibrosis, a type of bone marrow cancer. Participants had already been taking momelotinib in earlier studies and had not seen their disease get worse. The goal is to monitor long-term safety and track o…

This study looks at how well a combination of osimertinib (a targeted drug) and chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. About 532 adults with stage IIIB/IV or recurrent disease are being followed in real-world cli…

This study allows cancer patients who were already benefiting from atezolizumab in a previous Roche-sponsored trial to keep receiving the drug if they have no other local options. It includes 49 participants and focuses on safety and continued treatment access. The goal is to ens…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer that has not responded to standard treatments. The study has two parts: the first finds the safest dose of BI 765179 alone or with another drug (ezabenlim…

This study follows 500 children with growth hormone deficiency who are already taking somapacitan (a weekly injection) to see how safe it is over the long term. Researchers will track side effects, medication errors, and whether any children develop new health issues like cancer …

This study tests whether a modified clinical program can improve how doctors prevent blood clots (venous thromboembolism) in cancer patients receiving treatment. About 25 clinicians and their patients will take part. The program includes education for doctors and requires them to…

This study gathers medical information from up to 10,000 cancer patients who receive standard (non-experimental) treatments at the National Cancer Institute. It is designed for patients who are not in a research trial but need specialized care or follow-up. The goal is to build a…

This study examines medical records from Europe to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots return, and the costs involved. No new treatments are teste…

This study tests a new technology that adjusts the radiation beam to follow lung tumors as they move when a person breathes during treatment. About 20 adults with early-stage lung cancer or limited lung metastases will take part. The goal is to see if the system works reliably wi…

This study looks back at the medical records of 232 adults with cancer who took the immunotherapy drug M7824. The goal is to make a complete list of all side effects caused by the drug. By understanding these side effects better, doctors hope to prevent or reduce them in future c…